Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS Rating: 5.03, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.03 new
Vol. 6, Issue 3 (2017)

Usage the preparation of ribonucleic acid (Nuklex) in therapy of hepatitis C

Author(s):
Kondryn OYe, Vaskul NV and Virstiuk NH
Abstract:
Ukraine belongs to regions with high population infected by virus HC. Among the latest trends, HC treatment search find drugs can modulate inflammatory responses and antiviral innate immunity to fight viral infections. The aim of this study is to examine the effectiveness of the drug Nuklex in the treatment of patients with HC and the optimal therapeutic dose. It was determined that usage of Nuklex for treatment of hepatitis C is accompanied by a rapid disappearance of the main clinical symptoms, improvement of health in the patients, supports normalization of cytolytic liver function in patients with minimal or moderate activity hepatitis. The isolate usage of Nuklex as the only antiviral drug for hepatitis C patients with low initial viral load HCV (<800,000 IU / ml) in a daily dose of 1.5 g.
Pages: 164-167  |  811 Views  20 Downloads
How to cite this article:
Kondryn OYe, Vaskul NV, Virstiuk NH. Usage the preparation of ribonucleic acid (Nuklex) in therapy of hepatitis C. Pharma Innovation 2017;6(3):164-167.
The Pharma Innovation Journal